Cell and gene therapy program will be spun off as NsGene, CEO Jorgen Buus Lassen announced Sept. 30 at the Warburg Dillon Read Global Life Sciences Conference. Researchers, partners and collaborative agreements will all be shifted to NsGene. The group is considering therapies for Parkinson's disease, including a neublastin secreting cell line for protective therapy, and restorative therapy with dopaminergic neuronal precursor cell lines. "We expect that within three years, we can be in clinical studies within those new cell lines," Lassen said. Neurosearch aims to have financing for the spin off complete by the end of the year
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth